Literature DB >> 29268352

Atezolizumab in advanced non-small cell lung cancer.

Marius Ilie1,2,3, Paul Hofman1,2,3.   

Abstract

Entities:  

Year:  2017        PMID： 29268352      PMCID： PMC5723868          DOI： 10.21037/jtd.2017.09.73

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  19 in total

Review 1.  Assessment of the PD-L1 status by immunohistochemistry: challenges and perspectives for therapeutic strategies in lung cancer patients.

Authors:  Marius Ilie; Véronique Hofman; Manfred Dietel; Jean-Charles Soria; Paul Hofman
Journal:  Virchows Arch       Date:  2016-02-25       Impact factor: 4.064

2.  PD-L1 immunohistochemistry in clinical diagnostics of lung cancer: inter-pathologist variability is higher than assay variability.

Authors:  Hans Brunnström; Anna Johansson; Sofia Westbom-Fremer; Max Backman; Dijana Djureinovic; Annika Patthey; Martin Isaksson-Mettävainio; Miklos Gulyas; Patrick Micke
Journal:  Mod Pathol       Date:  2017-06-30       Impact factor: 7.842

3.  Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances: a potential issue for anti-PD-L1 therapeutic strategies.

Authors:  M Ilie; E Long-Mira; C Bence; C Butori; S Lassalle; L Bouhlel; L Fazzalari; K Zahaf; S Lalvée; K Washetine; J Mouroux; N Vénissac; M Poudenx; J Otto; J C Sabourin; C H Marquette; V Hofman; P Hofman
Journal:  Ann Oncol       Date:  2015-10-19       Impact factor: 32.976

4.  Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial.

Authors:  Roy S Herbst; Paul Baas; Dong-Wan Kim; Enriqueta Felip; José L Pérez-Gracia; Ji-Youn Han; Julian Molina; Joo-Hang Kim; Catherine Dubos Arvis; Myung-Ju Ahn; Margarita Majem; Mary J Fidler; Gilberto de Castro; Marcelo Garrido; Gregory M Lubiniecki; Yue Shentu; Ellie Im; Marisa Dolled-Filhart; Edward B Garon
Journal:  Lancet       Date:  2015-12-19       Impact factor: 79.321

5.  Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients.

Authors:  Roy S Herbst; Jean-Charles Soria; Marcin Kowanetz; Gregg D Fine; Omid Hamid; Michael S Gordon; Jeffery A Sosman; David F McDermott; John D Powderly; Scott N Gettinger; Holbrook E K Kohrt; Leora Horn; Donald P Lawrence; Sandra Rost; Maya Leabman; Yuanyuan Xiao; Ahmad Mokatrin; Hartmut Koeppen; Priti S Hegde; Ira Mellman; Daniel S Chen; F Stephen Hodi
Journal:  Nature       Date:  2014-11-27       Impact factor: 49.962

6.  PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project.

Authors:  Fred R Hirsch; Abigail McElhinny; Dave Stanforth; James Ranger-Moore; Malinka Jansson; Karina Kulangara; William Richardson; Penny Towne; Debra Hanks; Bharathi Vennapusa; Amita Mistry; Rasika Kalamegham; Steve Averbuch; James Novotny; Eric Rubin; Kenneth Emancipator; Ian McCaffery; J Andrew Williams; Jill Walker; John Longshore; Ming Sound Tsao; Keith M Kerr
Journal:  J Thorac Oncol       Date:  2016-11-29       Impact factor: 15.609

7.  Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.

Authors:  Martin Reck; Delvys Rodríguez-Abreu; Andrew G Robinson; Rina Hui; Tibor Csőszi; Andrea Fülöp; Maya Gottfried; Nir Peled; Ali Tafreshi; Sinead Cuffe; Mary O'Brien; Suman Rao; Katsuyuki Hotta; Melanie A Leiby; Gregory M Lubiniecki; Yue Shentu; Reshma Rangwala; Julie R Brahmer
Journal:  N Engl J Med       Date:  2016-10-08       Impact factor: 91.245

8.  Quantification of PD-L1 and PD-1 expression on tumor and immune cells in non-small cell lung cancer (NSCLC) using non-enzymatic tissue dissociation and flow cytometry.

Authors:  Amanda Chargin; Rian Morgan; Uma Sundram; Keith Shults; Ellen L Tsay; Navneet Ratti; Bruce K Patterson
Journal:  Cancer Immunol Immunother       Date:  2016-08-26       Impact factor: 6.968

9.  A Prospective, Multi-institutional, Pathologist-Based Assessment of 4 Immunohistochemistry Assays for PD-L1 Expression in Non-Small Cell Lung Cancer.

Authors:  David L Rimm; Gang Han; Janis M Taube; Eunhee S Yi; Julia A Bridge; Douglas B Flieder; Robert Homer; William W West; Hong Wu; Anja C Roden; Junya Fujimoto; Hui Yu; Robert Anders; Ashley Kowalewski; Christopher Rivard; Jamaal Rehman; Cory Batenchuk; Virginia Burns; Fred R Hirsch; Ignacio I Wistuba
Journal:  JAMA Oncol       Date:  2017-08-01       Impact factor: 31.777

10.  Changes in serum interleukin-8 (IL-8) levels reflect and predict response to anti-PD-1 treatment in melanoma and non-small-cell lung cancer patients.

Authors:  M F Sanmamed; J L Perez-Gracia; K A Schalper; J P Fusco; A Gonzalez; M E Rodriguez-Ruiz; C Oñate; G Perez; C Alfaro; S Martín-Algarra; M P Andueza; A Gurpide; M Morgado; J Wang; A Bacchiocchi; R Halaban; H Kluger; L Chen; M Sznol; I Melero
Journal:  Ann Oncol       Date:  2017-08-01       Impact factor: 32.976
View more
  4 in total

Review 1.  A Review of Monoclonal Antibody-Based Treatments in Non-small Cell Lung Cancer.

Authors:  Yunes Panahi; Amir Hossein Mohammadzadeh; Behzad Behnam; Hossein M Orafai; Tannaz Jamialahmadi; Amirhossein Sahebkar
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

2.  Characterization of dermatitis after PD-1/PD-L1 inhibitor therapy and association with multiple oncologic outcomes: A retrospective case-control study.

Authors:  Charles Kyung Min Lee; Shufeng Li; Duy Cong Tran; Gefei Alex Zhu; Jinah Kim; Bernice Y Kwong; Anne Lynn S Chang
Journal:  J Am Acad Dermatol       Date:  2018-05-29       Impact factor: 11.527

3.  Treatment effect and safety profile of salvage chemotherapy following immune checkpoint inhibitors in lung cancer.

Authors:  Mari Tone; Takehiro Izumo; Nobuyasu Awano; Naoyuki Kuse; Minoru Inomata; Tatsunori Jo; Hanako Yoshimura; Shingo Miyamoto; Hideo Kunitoh
Journal:  Lung Cancer Manag       Date:  2019-05-09

4.  Clinical outcomes in non-small-cell lung cancer patients receiving concurrent metformin and immune checkpoint inhibitors.

Authors:  Muhammad Z Afzal; Konstantin Dragnev; Tayyaba Sarwar; Keisuke Shirai
Journal:  Lung Cancer Manag       Date:  2019-05-07
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.